Last month, the FDA approved Donanemab, which could be used to treat Alzheimer’s disease. The drug is similar to another Alzheimer’s drug that received full FDA approval last year, Leqembi.
Both drugs target and remove amyloid in the brain and both require intravenous infusions. So how do they differ?
Dr. Jeremy Pruzin is a cognitive behavioral neurologist at the Banner Alzheimer's Institute.
"I think the biggest practical difference is that for Donanemab, the newer medication, in that clinical trial, once those amyloid plaques were completely cleared on a PET scan, the medication was stopped," Pruzin said.
Unlike the older drug Leqembi, which does not have a stop-point.
"And it's a bit of unknown what to do once those plaques are cleared," Pruzin said. "Is there a maintenance dose that should be given or can you stop?"
Pruzin says even though this new drug was approved, no one at Banner is being treated with it — yet.
"There’s a whole apparatus that needs to get mobilized, insurance. Given the side effects mentioned, we need a safety monitoring system to diagnose, get patients ready, get insurance covered, and make sure that all the appropriate MRIs and other things happen. And that takes a long time," Pruzin said.
Side effects can include possible swelling or bleeding of the brain.
-
There were more than 50 million licensed drivers in the U.S. over the age of 65 in 2022, according to the Centers for Disease Control and Prevention; that was a 77% increase since 2004. -
DoorDash has partnered with Kroger to provide grocery delivery access for SNAP recipients across the country, including in Arizona. -
When we think about autism spectrum disorder, we often think of children. But ASD isn’t new. It was formally recognized in 1980, which means those who received a diagnosis then are now middle-aged. Now, research shows there could be a link between Autism and Alzheimer's disease. -
A caregiver is facing charges of sexually abusing a resident living with dementia — and police say it was caught on camera. At the same time, lawmakers are considering a measure that would prevent assisted living facilities from prohibiting video cameras. -
The Alzheimer’s Association released its 2026 Facts and Figures report on Tuesday. The big takeaway this year is that people value brain health, but they don’t know how to protect it.
